Genetic Associations with Early-Onset Dupuytren's Contracture
Early-onset Dupuytren's contracture in a young woman without alcohol use has strong genetic underpinnings, with 26 identified genetic risk variants that predict not only disease development but also clinical severity, age of onset, and recurrence risk. 1, 2
Primary Genetic Risk Factors
The genetic architecture of Dupuytren's disease involves multiple pathways:
Core Genetic Variants
- 26 single-nucleotide polymorphisms (SNPs) have been identified through genome-wide association studies that collectively explain disease susceptibility 2, 3
- COL1A1 rs1800012: The A allele provides protective effects (OR 0.584), suggesting collagen metabolism dysregulation is central to pathogenesis 4
- SFRP4 rs1668347: The C allele increases disease risk (OR 1.831), implicating Wnt signaling pathway abnormalities 4
- MMP gene polymorphisms (MMP-1, MMP-8, MMP-13): These matrix metalloproteinase variants increase risk and affect tissue remodeling 5
Polygenic Risk Score (PRS) Implications
A weighted genetic risk score based on these 26 variants demonstrates:
- Significant association with early age of onset (before age 50) 1, 2
- Strong correlation with positive family history 1
- Independent prediction of surgical recurrence even after accounting for clinical risk factors 2
- Explains approximately 36% of ethnic prevalence differences in Dupuytren's disease 3
Shared Genetic Risk Factors with Other Conditions
Metabolic and Cardiovascular Associations
Diabetes and glycemic dysregulation share causal genetic pathways with Dupuytren's disease:
- Genetic liability for diabetes increases DD risk (OR 1.0157) through Mendelian randomization analysis 6
- This association persists independent of alcohol use 6
Lipid metabolism abnormalities demonstrate genetic overlap:
- High-density lipoprotein (HDL) levels show genetic correlation 1, 7
- Triglyceride levels are genetically associated with DD risk 1, 7
- Interestingly, there is a negative correlation between DD polygenic risk score and BMI genetic risk score 1, suggesting complex metabolic interactions
Musculoskeletal Conditions
(Osteo)arthritis shares genetic susceptibility with Dupuytren's disease 7, though the specific genetic variants remain under investigation. This connection is particularly relevant given that both conditions involve fibroproliferative processes and joint-related pathology.
Cardiovascular Disease Context
While not directly causing Dupuytren's contracture, the guidelines note that Dupuytren's contracture is a clinical sign used to screen for alcohol-related liver disease 8, 9. However, in your patient's case without alcohol consumption, this association is not relevant. The presence of DD in a non-drinking young woman strongly suggests primary genetic etiology rather than secondary metabolic causes.
Clinical Implications for This Patient
Risk Stratification
For a woman under 40 with early-onset disease:
- High genetic burden is virtually certain given the age of presentation 1, 2
- Expect bilateral disease development (genetically associated) 2
- Increased risk of ectopic manifestations (Ledderhose disease of feet, Peyronie's disease) 2
- Higher probability of surgical recurrence regardless of initial treatment choice 2
Family Screening Considerations
- First-degree relatives have substantially elevated risk given the autosomal dominant inheritance pattern with incomplete penetrance 2
- Family members should be counseled about genetic predisposition
- However, routine genetic testing for common DD polymorphisms does not currently add to clinical management and cannot be recommended for diagnostic or treatment decisions 10
Associated Conditions to Monitor
Screen this patient for:
- Diabetes/prediabetes: Check fasting glucose and HbA1c given the causal genetic relationship 6
- Lipid abnormalities: Obtain lipid panel (HDL, triglycerides) 1, 7
- Joint symptoms: Assess for early arthritis given the genetic overlap 7
Important Caveats
The observed genetic effect sizes are modest (ORs typically 1.01-1.83), consistent with DD being a multifactorial disease 6. The polygenic risk score explains clinical variation but represents population-level risk associations rather than deterministic individual predictions 1.
Genetic testing is not recommended for routine clinical use in DD management, as it does not currently change treatment decisions 10. The primary value of understanding genetic architecture lies in prognostication and family counseling rather than therapeutic selection.